Comparison

iCare PATIENT2 vs MVSS Scribe+

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

iCare PATIENT2

Manage your intraocular pressure (IOP) measurements and track changes with this app. It allows you to record, analyze, and share your IOP results with your ophthalmologist to aid in glaucoma treatment decisions. Requires a compatible tonometer.

Highlights
  • Track intraocular pressure (IOP) measurements
  • Visualize IOP changes with graphs
  • Transfer measurements via Bluetooth
  • Share results with healthcare providers
  • Store measurements in the cloud
Read full description

iCare PATIENT2 is a smart way to manage your intraocular pressure (IOP) measurements and track your IOP changes. As a patient, you can actively contribute to the management of your glaucoma by taking frequent IOP measurements at home and outside of office hours. The iCare PATIENT2 app is used together with the iCare HOME2 tonometer. The IOP measurements from the iCare HOME2 tonometer can be transferred to the iCare PATIENT2 app and further to the iCare CLOUD or to your healthcare provider’s database. The application allows you to record, track and analyze your IOP measurement results. With the iCare PATIENT2 app, you can share your IOP results with your ophthalmologist. Daily measurements can help your ophthalmologist get a better overview of changes in your IOP status. This way, your ophthalmologist can make more informed decisions regarding your glaucoma treatment. The iCare HOME2 tonometer is easy to use in your daily routine. The iCare tonometers use rebound technology, where the rapid and light touch of the measurement probe provides a comfortable measurement without air puff or anesthetics. The results from iCare HOME2 tonometer are reliable as has been proven in multiple scientific studies. Features: - Store and access your IOP measurement results anywhere, anytime. - View your IOP measurement results in a graph to better visualize and detect important changes in your IOP. - Transfer your IOP measurements from your iCare HOME2 tonometer via Bluetooth. - Measurement results can be stored in the iCare CLOUD or in the database of your healthcare provider. Your healthcare provider must have an iCare CLINIC account in order to use this feature. Note: Read the “iCare PATIENT2 Instruction manual for iOS”, “iCare PATIENT2 and EXPORT Quick Guide for mobile phones and PC” and “iCare HOME2 Instruction Manual” before using iCare PATIENT2 app with iCare HOME2 tonometer. If you need help in using the iCare HOME2 tonometer, contact your healthcare professional. Use the tonometer only for measuring intraocular pressure. Any other use is improper. The manufacturer is not liable for any damage arising from improper use, or for the consequences of such use. Patients must not modify or discontinue their treatment plan without receiving guidance from a healthcare professional. Seek a doctor’s advice in addition to using this app and before making any medical decisions.

About

MVSS Scribe+

Features
Read full description

Mountain View Scribe Services (MVSS) was founded on the principle of improving patient care and provider satisfaction through better documentation. With an emphasis on providing scribe excellence in the field of medical documentation, MVSS partners with medical providers not only to facilitate a personalized medical experience for patients but also to maximize worry-free documentation for all affiliated providers. From Emergency Departments to specialty clinics across Southern and Central California, MVSS has built its reputation on the personal touch, attention to detail, and flexibility that make a scribe program truly great. MVSS Scribe+ extends that same standard of excellence into an intelligent, AI-powered tool, available anywhere, anytime. Designed for the modern healthcare practitioner, MVSS Scribe+ listens to your patient encounters and instantly generates accurate, HIPAA-compliant clinical documentation, so you can focus on your patients instead of your paperwork.

Screenshots

iCare PATIENT24 screens
MVSS Scribe+4 screens

Verdict

The call

The clearest difference is update cadence: MVSS Scribe+ at every 5 days against iCare PATIENT2's every 5 months. iCare PATIENT2's advantage is device support (3 vs 1) and iOS requirement (15.0 vs 17.0). On price, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

UpkeepUpdate frequency

iCare PATIENT2 ships an update every 5 months, MVSS Scribe+ every 5 days. The most recent releases landed on November 13, 2026 and November 5, 2026 respectively.

Scorecard3 real differences · 7 level
iCare PATIENT2 versus MVSS Scribe+: the parameters behind the verdict, then further details
ParameteriCare PATIENT2MVSS Scribe+
PriceFreeFree
Rating2.3 (11 ratings) — better—
Positive reviews25.0% of reviews—
Number of ratings11 — better—
Update frequencyEvery 5 monthsEvery 5 days — better
AdsNoNo
In-app purchasesNoNo
MonetizationFree—
DevicesiPhone, iPad, iPod — betteriPhone
Requires iOS15.0 — better17.0
Further details — not scored
Size32 MB9 MB
Age rating17+4+
DeveloperIcare Finland OyAtlas Medical Solutions, Inc.

In-app purchases

None

iCare PATIENT2

No in-app purchases

None

MVSS Scribe+

No in-app purchases

Questions

Is iCare PATIENT2 free?
iCare PATIENT2 is free to download, with no in-app purchases.
Is MVSS Scribe+ free?
MVSS Scribe+ is free to download, with no in-app purchases.
Do iCare PATIENT2 or MVSS Scribe+ have ads?
Neither iCare PATIENT2 nor MVSS Scribe+ shows ads.
Which is updated more often, iCare PATIENT2 or MVSS Scribe+?
iCare PATIENT2 ships an update every 5 months, and MVSS Scribe+ every 5 days. Most recently, iCare PATIENT2 was updated on November 13, 2026 and MVSS Scribe+ on November 5, 2026.

Other comparisons